Lexaria Bioscience appoints Catherine Turkel to board; grants stock options, receives Mexican patent

Lexaria Bioscience Corp.

Appointed Catherine Turkel, PharmD, PhD as independent director; board expanded to six members effective Sept 2, 2022.
Dr. Turkel brings 20+ years pharma exec experience; led Allergan's BOTOX Chronic Migraine registration program.
Compensation set parallel to other independent directors; contributes to drug development and Nasdaq diversity goals.
Granted 103,500 options at $2.91 expiring Aug 2027 to employees/directors/officers; 3,400 options at $3.04 expiring Sep 2027 to a director.
Awarded Mexican patent #390001 for stable ready-to-drink lipophilic active agent beverage compositions (grant date Feb 10, 2022).

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catherine C. Turkel

Independent Director

LEXX · Lexaria Bioscience Corp.

Effective: 2022-09-02
Filed: September 2, 2022, 7:59 PM ET

On September 2, 2022 (the “Effective Date”) the board of directors of Lexaria Bioscience Corp., in accordance with Nevada corporate laws, increased the size of the board to six members and appointed Catherine C. Turkel, PharmD, PhD as an additional independent director to hold such position until the next shareholder’s meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Catherine C. Turkel was appointed as Independent Director at Lexaria Bioscience Corp..

Action: appointed
Role: Independent Director

Exact text from the filing

On September 2, 2022 (the “Effective Date”) the board of directors of Lexaria Bioscience Corp., in accordance with Nevada corporate laws, increased the size of the board to six members and appointed Catherine C. Turkel, PharmD, PhD as an additional independent director to hold such position until the next shareholder’s meeting.

View on SEC.gov

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-22-001913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.